U.S. Markets closed

Quest PharmaTech Inc. (QPT.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.110.00 (0.00%)
At close: 9:34AM EDT
People also watch
MIR.VPYT.VCZO.VICO.VMBI.V

Quest PharmaTech Inc.

8123 Roper Road NW
Edmonton, AB T6E 6S4
Canada
780-448-1400
http://www.questpharmatech.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Dr. Ragupathy Madiyalakan Ph.D.Chief Exec. Officer and Director463.78kN/AN/A
Mr. Pierre Vermette C.A.Chief Financial Officer96.69kN/AN/A
Mr. Thomas Woo M.Sc.VP of Product Devel.109.17kN/AN/A
Mr. Roger AndrewsHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Douglas C. BachmanVP of Corp. Devel.N/AN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company operates in two segments, Biopharmaceutical/Pharmaceutical Products and Consumer/Cosmetic Products. It develops products for treatment of cancer by combining immunotherapeutic antibodies with immunoglobulin G or E, chemotherapy, immune-adjuvants, or photodynamic therapy. The company’s lead product candidate is Oregovomab, a monoclonal antibody for the treatment of ovarian cancer, which is in Phase II clinical trial. It also owns the Photodynamic therapy technology for oncology and dermatology applications; markets Bellus Skin serum, an anti-wrinkle skin care product; and develops Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Corporate Governance

Quest PharmaTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.